SRC KINASE INHIBITION AS TREATMENT FOR LYMPANGIOLEIOMYOMATOSIS AND TUBEROUS SCLEROSIS

摘要

Provided herein are methods of treating lymphangioleiomyomatosis or tuberous sclerosis complex using one or more Src inhibitors. The Src inhibitor may be saracatinib, in some cases. In particular aspects, an individual being treated with methods of the disclosure are also provided one or more inhibitors of mTOR.